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The antiviral activity of the organic extract (OE) ofEupatorium buniifolium against poliovirus was determined by in vitro assays with
an effective concentration 50 (EC
50
) of 23.3 ± 3.3 𝜇g/mL. Bioassay-guided fractionation of the OE allowed the isolation of an active
principle that was identified by spectroscopic methods (1H- and 13C-NMR, EI-MS, UV, and IR spectroscopy) as the benzofuran
euparin.The plaque reduction assay in Vero cells was used to assess the antiviral activity of euparin against poliovirus types 1, 2, and
3 with EC
50
values of 0.47, 0.12, and 0.15 𝜇g/mL, respectively. Moreover, this compound showed high selectivity indexes of 284.9,
1068, and 854.7, respectively. In order to identify the mechanism by which euparin exerts its antiviral activity, the virucidal effect,
the pretreatment of Vero cells, and the time of action on one viral replication cycle were evaluated. Results obtained demonstrated
that euparin exerts its effect during the early events of the replication cycle, from the virus adsorption to cells up to the first twenty
minutes after infection. This is the first report on the presence of euparin in E. buniifolium and its antiviral activity.
1. Introduction
Poliomyelitis is caused by poliovirus (PV), which can affect
the nervous system causing permanent paralysis. PV is an
RNA virus that belongs to the genus Enterovirus of the large
family of Picornaviridae.There are three serotypes of PV (i.e.,
PV-1, PV-2, and PV-3).
Two trivalent polio vaccines have been available since
1961: the intramuscular inactivated vaccine of Salk and the
oral attenuated vaccine of Sabin. Both of them stimulate the
production of neutralizing antibodies antipolioviruses that
protect from the disease. Polioviruses have been eradicated
from the United States in 1980 and from the Western
Hemisphere in 1991. In 1999, the Global Polio Eradication
Initiative wiped out PV-2. Nowadays, and according to the
World Health Organization, poliomyelitis remains endemic
in Afghanistan, Nigeria, and Pakistan and transmission has
been reestablished in three countries which were previously
declared as polio-free (Angola, Chad, and the Democratic
Republic of the Congo) [1]. 1
In 2006, the “Committee on Development of a Polio
Antiviral and Its Potential Role in Global Poliomyelitis
Eradication” highlighted the importance of the potential role
of an antiviral drug in the context of polio eradication [2]
that would be used: (i) for immunodeficient people who
are chronically shedding poliovirus, (ii) for people exposed
to poliovirus, for example, through unintentional labora-
tory exposure, (iii) for communities exposed to circulating
vaccine-derived poliovirus outbreaks in the posteradication
era (likely in conjunction with inactivated polio vaccine).
One strategy for the development of antiviral agents is
the search for novel compounds from natural sources. A
variety of lead molecules, mainly those isolated from higher
plants, have already been reported: terpenoids, flavonoids,
coumarins, alkaloids, and lignans [3–6]. Among the numer-
ous medicinal plants growing in our country, Eupatorium
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buniifolium Hook. et Arn. (Asteraceae), popularly known as
“romerillo,” “romerillo Colorado,” or “chilca,” is traditionally
used as disinfectant and against rheumatic pains [7, 8]. It
has been reported to possess in vitro anti-inflammatory [9],
antioxidant [10], and trypanocidal [11] activities and that
some of its extracts can inhibit Herpes simplex virus type I
replication [12] and reduce Herpes suis virus viral infectivity
[13].
In this study, we report the antiviral activity of the organic
extract of Eupatorium buniifolium and the isolation and
identification of a new antipoliovirus compound, by bioassay-
guided fractionation and its possible mechanisms of action.
2. Materials and Methods
2.1. Plant Material. The aerial parts of Eupatorium buni-
ifolium were collected in Departamento Taf´ı del Valle in the
province of Tucuma´n, Argentina, in May 2009. The plant
material was identified by A. Slanis-B. Juarez and a voucher
specimen (Slanis-Juarez 1043 or LIL609703) is deposited at
the Herbarium of the Fundacio´n Miguel A. Lillo, University
of Tucuma´n, Argentina.
2.2. Extraction of Plant Material. Air-dried and ground
aerial parts (500 g) were extracted by maceration with
dichloromethane :methanol (1 : 1) for 24 h and then vacuum-
filtered. The process was repeated twice and the filtrates were
combined and taken to dryness under vacuum to obtain
the organic extract (OE). The marc was air-dried and then
extracted with water (500mL) under the same conditions.
The resulting aqueous extract (AE) was freeze-dried.
2.3. Bioassay-Guided Fractionation of E. buniifolium
CH
2
Cl
2
:MeOH (1 : 1) Extract (OE) and Isolation of the
Active Compound. The fractionation of OE (30 g) was done
by open column chromatography loaded with silicagel
60 (Merck, 0.063–0.2mm/70–230mesh; 300 g) and eluted
with a step gradient of hexane : ethylacetate (100 : 0 to
0 : 100) and ethylacetate :methanol (100 : 0 to 0 : 100). Ten
fractions (250mL) were obtained and monitored by thin
layer chromatography (TLC), carried out on silica gel plates
with hexane : ethylacetate (1 : 1) as mobile phase. Fractions
with the same chromatographic profile were combined into
five fractions (F
1
–F
5
).2
Fraction F
2
(2.1 g) was purified by column chromatog-
raphy on silicagel 60 (100 g) and eluted with 100% hex-
ane, hexane : ethylacetate (9 : 1; 7 : 3; 1 : 1), 100% ethylacetate,
ethylacetate :methanol (1 : 1), and 100% methanol, obtaining
42 fractions of 15mL each, that were combined afterwards
into 17 subfractions (F
2.I–F2.XVII) according to their TLC
profile. From fraction F
2.VI, euparin crystallized as yellow
needles. Melting point was determined in a Thomas Hoover
apparatus.
2.4. Spectrometric Analyses. Euparin was identified by
nuclear magnetic resonance 1H-NMR and 13C-NMR
(NMR Varian Inova, 500MHz in CDCl3), electron impact-
mass spectrometry (EI-MS) (Agilent 5973), ultraviolet
spectroscopy (UV) (Jasco V-630), and infrared spectroscopy
(IR) (Nicolet 380 FT-IR-Smart Multi Bruce HATR, Zn Se
45∘).
2.5. Cells and Viruses. Vero cells (ATCC CCL 81) were
obtained from Asociacio´n Banco Argentino de Ce´lulas and
cultured at 37∘C in a 5% CO
2
incubator in growth medium:
Eagle’s minimal essential medium (Gibco) supplemented
with 10% fetal bovine serum (FBS, PAA), 100 𝜇g/mL strepto-
mycin, 100 IU/mL penicillin, 2mM L-glutamine, and 100𝜇M
nonessential amino acids (Gibco). Infection Medium (IM),
which was used for the antiviral assays, was the same as the
growth medium but with 2% FBS. Plaque medium (PM) was
IM containing 1% methylcellulose (Sigma). Poliovirus types
1, 2, and 3 (PV-1, PV-2, and PV-3) Sabin strains and herpes
simplex virus type 1 (HSV-1) F strain were kindly provided
by Dr. Mar´ıa Cecilia Freire (ANLIS-Instituto Dr. Carlos G.
Malbra´n, Argentina) and Dr. Albert Epstein, respectively.
Vesicular stomatitis virus (VSV), Indiana strain (ATCC VR-
1421), was purchased from ATCC. All virus stocks were
stored at −70∘C until used. Viral stocks were propagated and
quantified in Vero cells. The number of plaque forming units
per mL (PFU/mL) was determined by the plaque assay for
virus quantification.
2.6. Viral Cytopathic Effect Reduction Assay. Antiviral activi-
ties of E. buniifolium extracts (OE and AE) against PV-1 were
performed bymeasuring the reduction of the viral cytopathic
effect (CPE). Confluent Vero cells monolayers growing in 96-
well plates after 24 h of culture were infected with PV-1 at a
multiplicity of infection (m.o.i) of 0.01 PFU/cell in presence
of both 25 and 100 𝜇g/mL of OE diluted in dimethyl sulfoxide
(DMSO) and AE diluted in sterile distilled water. Control
viruses and mock-infected cells were included in each plate.
Then, the plate was incubated (37∘C, 5% CO
2
) until 90%
of viral CPE was reached at control viruses. The reduction
of viral CPE was determined by assessment of cell viability
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTS/PMS) assay (CellTiter 96 Aqueous-Promega,
Madison, WI) according to the manufacturer’s instructions.
The absorbance at 490 nm was read in an automatic plate
reader (Multi-Mode Microplate Reader-SynergyTM HT-
BioTek) according to % CPE reduction = [(Abstreated −
Abscontrol virus)/(Abscellular control − Abscontrol virus)] ∗ 100.
2.7. Cytotoxicity Assay. Cell viability was assessed by the
MTS/PMS test as previously described [14]. Briefly, subcon-
fluent monolayers of Vero cells cultures (8 × 103 cells/well;
24 h) in 96-well plates were exposed to twofold dilutions
of OE, fractions F
2
–F
4
, and euparin in DMSO for 72 h
at 37∘C. Cellular controls were incubated under the same
conditions in presence of growth medium without drug. Cell
viability was calculated as [Abstreated cells/Abscellular control] ×
100. The cytotoxic concentration 50 (CC
50
) is defined as the
concentration that reduces cell viability by 50% with respect
to cell control and is determined from dose-response curves.
The maximum noncytotoxic concentration (MNCC) is the
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maximum concentration of OE, fraction, or euparin that
leaves 100% of viable cells.
2.8. Plaque Reduction Assay. Confluent Vero cell monolayers
seeded in 24-well plates (24 h; 5% CO
2
; 37∘C) were infected
with 100 PFU of PV-1/well in presence of serial twofold
dilutions from theMNCC of E. buniifoliumOE, fractions F
1
–
F
5
, or euparin. Following 45min of adsorption at 37∘C, the
viral inoculum was removed; cell monolayers were washed
twice and overlaid with PM supplemented with the same
concentrations of OE, fractions F
1
–F
5
or euparin added
during the adsorption period. Mock-infected cells and virus
control were included. After 24–48 h of incubation cell
monolayerswere fixed and stainedwith 0.75% crystal violet in
methanol : water (40 : 60) and viral plaqueswere counted.The
effective concentration 50 (EC
50
) value is the concentration
of OE, fraction, or euparin that reduces the number of
viral plaques by 50% with respect to the viral control and
was calculated by regression analysis of the dose-response
curves generated with the data. Reduction of plaques (%) was
calculated as [1−( n∘ plaques treated/ n
∘ plaquescontrol virus)]×
100. The selectivity index (SI) was calculated as CC
50
/EC
50
.
The antiviral activity of E. buniifolium OE and euparin was
also determined against PV-2, PV-3, HSV-1, HSV-2, and VSV
by reduction viral plaque assays in Vero cells monolayers as
described earlier.3
2.9. Virucidal Assay of Euparin. PV-1 (1.0 × 106 PFU) was
incubated at room temperature (r.t.) or 37∘C for 30min in
IM with or without 10𝜇g/mL (10X EC
90
) of euparin. The
residual infectious virus particles were determined by viral
plaque assays in Vero cell monolayers.4
2.10. Effect of Vero Cell Pretreatment with Euparin. Pretreat-
ment of Vero cells with euparin was evaluated as previously
described [14]. Vero cell monolayers were seeded in 24-well
plates. After 24 h (5%CO
2
incubator, 37∘C), cells werewashed
twice with phosphate buffer saline (PBS) and treated with
1.0 and 10 𝜇g/mL of euparin in IM, corresponding to EC
90
and 10X EC
90
, respectively. After 7 h incubation at 37∘C, the
medium was removed; cell monolayers were washed three
times with PBS and infected with 100 PFU/well of PV-1 in
0.1mL of IM. Following 45min of adsorption at 37∘C, the
virus inoculum was removed and PM was added. After 24 h,
cells were fixed and stained and viral plaques were counted.
2.11. Time of Addition Assay of Euparin. To study the effect
of euparin in the adsorption and post adsorption events of
PV-1 in Vero cells, three different treatments at 1.0𝜇g/mL
(1X EC
90
) were evaluated: (i) only during adsorption period
(Adsorption); (ii) after adsorption and until the end of the
experiment (After Adsorption), and (iii) during and after
the adsorption (Throughout). Briefly, Vero cell monolayers
cultured in 24-well plates were precooled for 1 h at 4∘C.
Cells were then infected with 100 PFU of PV-1 virus/well in
presence or absence of euparin and further incubated at 4∘C
for 1 h. Cell monolayers were washed with PBS, and then
PM with or without euparin was added. After 24 h, the viral
plaques were counted.
2.12. Effect of Time Addition of Euparin on the One-Step
Replication Cycle. Confluent Vero cell monolayers cultured
in a 24-well plate were infected with PV-1 (m.o.i. = 5) for 1 h
at 4∘C. Following the adsorption period, cells were washed
three times, and 10 𝜇g/mL of euparin was added at different
hours after infection (h p.i.): 0, 1, 2, 3, 4, 5, 6, and 7 or at
different minutes p.i.: 0, 10, 20, 30, 40, 50, and 60. Cells were
further incubated up to 8 h. At this time, the supernatants
were collected, clarified by centrifugation (3,500×g at 4∘C),
and the extracellular virus production was determined by
viral plaque assays.
2.13. Statistical Analysis. Data are presented as means ± SD
of three independent assays. The EC
50
and CC
50
values were
calculated using GraphPad Prism programme v. 5.01. Statisti-
cal differences between different treatments were determined
using one way ANOVA with Tukey’s posttest. Differences
were considered significant when the 𝑃 value was less than
0.05.
3. Results
3.1. Antiviral Activity of E. buniifolium OE and AE against
PV-1. The antiviral activity of E. buniifolium OE and AE
was determined against PV-1 by the viral cytopathic effect
reduction assay. The results obtained showed that only OE
inhibited PV-1 replication at the two concentrations tested (25
and 100 𝜇g/mL) with CPE reduction values higher than 50%
(data not shown).
3.2. Bioassay Guided Fractionation of E. buniifolium OE and
Structure Elucidation of Euparin. Fractionation of OE, by
chromatographic techniques, yielded five fractions (F
1
–F
5
)
which were assayed for their in vitro anti-PV-1 activity by
the plaque reduction assay (Figure 1 and Table 1). Further
purification of F
2
yielded subfractions F
2.I–F2.XVII (Figure 1).
From fraction F
2.VI a major anti-PV compound (39mg;
130.0mg/100 g dried extract) was isolated and identified
as euparin (purity > 95%, by High Performance Liquid
Chromatography (HPLC); m.p. 120–122∘C) by comparison of
its spectral data with the literature values (Figure 2) [15, 16].
3.3. Spectral Data of Euparin. Euparin presented the follow-
ing spectral data: UV 𝜆max (nm)MeOH: 260, 356; IR (KBr),
]max (cm
−1): 3388 (OH), 1470 (aromatic), 1636 (C=COR); 1H
NMR (MeOH-𝑑4), 𝛿 (ppm): 8.18 (1H, s, H-4); 6.95 (1H, d,
𝐽 = 0.5Hz H3); 6.78 (1H, s, H7); 5.74 (1H, m, H11a); 5.21
(1H, m, H11b); 2.72 (3H, s, H-14); 2.14 (3H, s, H-12). 13C
NMR (DMSO-d6), 𝛿 (ppm): 204.60 (s, C-13), 161.24 (s, C-8),
159.49 (s, C-6), 157.64 (s, C-2), 132.45 (s, C-5), 124.27 (d, C-4),
121.91 (s, C-9), 116.79 (s, C-10), 112.23 (t, C-11), 102.54 (d, C-3),
98.24 (d, C-7), 25.59 (q, C-14), 17.85 (q, C-12); EI-MS (𝑚/𝑧,
rel.int.) 218 (19.30), 217 (48.18), 216 (68.16) [M]+, 203 (2.52),
202 (16.22), 201 (100.00), 173 (26.88). 5
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Table 1: Cytotoxicity and antiviral activity of extracts, fractions, and euparin against PV-1, PV-2, and PV-3.
CC50 (𝜇g/mL)
PV-1 PV-2 PV-3
EC50
(𝜇g/mL)
EC90
(𝜇g/mL) SI
EC50
(𝜇g/mL)
EC90
(𝜇g/mL) SI
EC50
(𝜇g/mL)
EC90
(𝜇g/mL) SI
E. buniifolium OE 114.8 ± 1.8 23.3 ± 3.3 47.2 ± 2.8 5.5 25.0 ± 1.8 41.5 ± 3.4 4.6 21.1 ± 2.5 38.8 ± 5.7 4.8
E. buniifolium AE >2000 Inactive — — Inactive — — Inactive — —
Fraction F1 n.d. Inactive — — n.d. — — n.d. — —
Fraction F2 254.2 ± 1.2 13.3 ± 2.6 32.6 ± 1.4 19 n.d. — — n.d. — —
Fraction F3 140.8 ± 2.7 27.8 ± 1.1 43.3 ± 2.4 5.1 n.d. — — n.d. — —
Fraction F4 205.1 ± 3.4 19.4 ± 1.6 27.2 ± 0.2 10.6 n.d. — — n.d. — —
Fraction F5 n.d. Inactive — — n.d. — — n.d. — —
Euparin 128.2 ± 2.2 0.47 ± 0.05 1.01 ± 0.01 284.9 0.12 ± 0.01 0.52 ± 0.01 1068 0.15 ± 0.01 0.36 ± 0.07 854.7
The maximal concentration tested for antiviral activity was 100 𝜇g/mL; if the extract of fraction was unable to inhibit viral replication at this concentration
was considered inactive.
n.d.: not determined.
CC50: concentration that reduces cell viability by 50% with respect to cell control; EC50: concentration that reduces the number of viral plaques by 50% with
respect to the viral control; EC90: concentration that reduces the number of viral plaques by 90% with respect to the viral control; SI = CC50/EC50.
Column chromatography (silicagel 60) eluted with solvents of increasing polarity
Column chromatography (silicagel 60)
E. buniifolium OE
Cl2CH2
Fraction F1 Fraction F2 Fraction F3 Fraction F4 Fraction F5
Hx 100% EtOAc 100% MeOH 100%
: MeOH 1 : 1
Hx : EtOAc 1 : 1 EtOAc : MeOH 1 : 1
F2.I –F2.XVII
F2.VI : euparin
Figure 1: Bioassay-guided fractionation of Eupatorium buniifolium organic extract (OE).
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Figure 2: Chemical structure of euparin: 1-[6-hydroxy-2-(1-
methylethenyl)-5-benzofuranyl] ethanone, C
13
H
12
O
3
, MW: 216.23.
3.4. Cytotoxicity Assay. The cytotoxic effect of E. bunnifolium
OE, fraction F
2
and euparin, on Vero cells, was evaluated by
theMTS/PMS assay and expressed as cell viability percentage.
When cells were treated with OE, fraction F
2
, or euparin,
CC
50
values were 114.8 ± 1.8 𝜇g/mL, 254.2 ± 1.2 𝜇g/mL, and
128.2 ± 2.2 𝜇g/mL, respectively (Table 1). 6
3.5. Antiviral Activity. The antiviral activity of E. buniifolium
organic extract (OE), fractions F
1
–F
5
, and euparin against
PV-1 was evaluated by the plaque reduction assay. As showed
in Table 1, EC
50
values for OE, fraction F
2
, and euparin were
23.3 ± 3.3 𝜇g/mL; 13.3 ± 2.6 𝜇g/mL and 0.47 ± 0.05 𝜇g/mL,
respectively. The SI values for OE, F
2
, and euparin were 5.5,
19 and 284.9, respectively.
The antiviral activity of OE and euparin was also eval-
uated against PV-2, PV-3, HSV-1, HSV-2, and VSV by the
plaque reduction assays. Results showed that OE was active
against PV-2, and PV-3 with EC
50
values of 25.0 ± 1.8 𝜇g/mL
and 21.1 ± 2.5 𝜇g/mL, respectively. Euparin showed EC
50
values of 0.12±0.01 𝜇g/mL (SI = 1068) and 0.15±0.01 𝜇g/mL
(SI = 854.7) against PV-2 and PV-3 respectively (Table 1).
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Figure 3: Virucidal activity (a) and the effect of pretreatment of
Vero cells with euparin (b). The virucidal activity of 10 𝜇g/mL (10X
EC
90
) at 37∘C and r.t. and the pretreatment with 1.0 and 10 𝜇g/mL
were evaluated against PV-1. Data represent % of virus inhibition
compared to untreated controls as mean ± SD (𝑛 = 3). Experiments
were done in quadruplicate.
0
20
40
60
80
100
120
Adsorption
Adsorption
After adsorption
After adsorption
Throughout
Throughout
Vi
ra
l i
nh
ib
iti
on
 (%
)
¶¶
Figure 4: Percentage of viral inhibition against PV-1 under different
experimental conditions. Euparin (1.0𝜇g/mL) was present at the
indicated times. Data represents % of virus inhibition obtained at
each condition with respect to untreated control as mean ± SD
(𝑛 = 3). Experiments were done in quadruplicate. ¶𝑃 < 0.001
versus Adsorption.
Neither E. buniifolium OE nor euparin showed antiviral
activity against HSV-1, HSV-2, and VSV.7
3.6. Virucidal Activity and Effect of Vero Cells Pretreatment
with Euparin on PV-1 Infection. No significant reduction of
viral infectivity was observed when the viruses were in direct
contact (treated) with concentrations of euparin as high as
10 𝜇g/mL (10X EC
90
). These results suggested that euparin
did not exert a virucidal activity against PV-1 (Figure 3(a)).
Moreover, the addition of 1.0 and 10 𝜇g/mL of euparin to
Vero cells monolayers 7 h before infection with PV-1 did not
exert any reduction in viral infection.Thus, it can be deduced
that no antiviral activity was induced in these cells during the
pretreatment with euparin (Figure 3(b)). 8
3.7. Time of Addition of Euparin. To determine the time of the
viral cycle at which euparin interferes with viral replication,
an assay was carried out by adding 1.0 𝜇g/mL (1X EC
90
)
of this compound during the different infection periods.
The maximum inhibition was obtained when the compound
was present in the postadsorption period or throughout the
infection time (Figure 4).
3.8. Effect of Time Addition of Euparin on the One-Step Viral
Replication Cycle of PV-1. The effect of addition of euparin
on one cycle of virus replication was evaluated to define
which step of PV-1 replication is inhibited. Euparinwas added
at different h p.i. and then extracellular viral production
was evaluated at 8 h p.i. Viral titers were markedly reduced
when the compound was added during the first hour p.i.,
after which this effect was not observed, suggesting that
euparin may be acting at a time point between 0 and 1 h p.i.
(Figure 5(a)). The same experiment was repeated but adding
it during the first h p.i., every 10min.The results (Figure 5(b))
showed that euparin is needed to be present before the first
20min p.i. to obtain the maximal inhibitory effect.
4. Discussion
Throughout history, medicinal plants have been widely used
to treat a great variety of diseases, and the majority of
new drugs have been developed from natural products and
from compounds derived from these sources. The research
and development of new natural compounds with antiviral
activity have attracted the researchers’ interest [17, 18] as good
candidates suitable for furthermodification and optimization
of bioactivity. 9
In this context, we have evaluated the antiviral activity of
the medicinal plant E. buniifolium against PV-1. Among the
extracts tested, only the organic extract (OE) exerted antiviral
activity (EC
50
= 23.3 ± 3.3 𝜇g/mL).
This finding prompted us to perform a bioassay-guided
fractionation of OE by chromatographic techniques. Among
all the fractions obtained (F
1
–F
5
), F
2
showed the highest
antiviral activity (EC
50
= 13.3 ± 2.6 𝜇g/mL) and was selected
for further purification. From this fraction a bioactive com-
pound was isolated and identified as the benzofuran euparin
(EC
50
= 0.47 ± 0.05 𝜇g/mL). The EC
50
values obtained for
OE, fraction F
2
, and euparin demonstrated that a progressive
increase in the anti PV-1 activity was gained during the
purification process.
Euparin was first isolated from Eupatorium purpureum
[19] and its chemical structure was defined as a benzofuran
by Kamthong and Robertson in 1939 [20].
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Figure 5: Effect of addition of euparin on the PV-1 production during a one-step replication cycle. Vero cell monolayers were infected atm.o.i.
= 5 and euparin (10𝜇g/mL) was added at different h p.i. (a) or min p.i. (b), after the adsorption period. At 8 h p.i. at 37∘C, the extracellular
PV-1 production was determined by the viral plaque assay. ∗𝑃 < 0.01 versus 0 h p.i.; versus 0 min p.i.; versus 10min p.i. #𝑃 < 0.05 versus 0 h
p.i.; versus 0min p.i. ¶𝑃 < 0.001 versus 0min p.i.; 10 min p.i.
Natural benzofurans are heterocyclic compounds fre-
quently synthesized by species of the Asteraceae family. Ben-
zofurans and their derivatives show a wide range of pharma-
cological properties such as antiviral, antimicrobial, antifun-
gal, anti-inflammatory, antiallergic, and cytotoxic activities
[21–27]. Although many biological assays employing euparin
have been undertaken, only a few pharmacological activities
have been demonstrated [28, 29]. However, its antiviral
activity had not been evaluated so far.
Euparin showed low cytotoxicity on Vero cells while
exerting a significant antiviral activity against the three types
of polioviruses (PV-1, PV-2, and PV-3), and consequently
high selectivity has been demonstrated with SI values of
284.9, 1068, and 854.7, respectively.
These results prompted us to characterize the probable
mechanism of action. As euparin showed neither virucidal
activity nor protection of the cells in the pretreatment, we
decided to evaluate which step of viral cycle was inhibited by
this compound.
Time of addition assays demonstrated that euparin com-
pletely inhibited the viral plaques formation when it was
added in the postadsorption period. This result was later
confirmedwith time of addition assay on one-step replication
viral cycle where we observed that the maximum inhibition
was obtained when euparin was added during the first twenty
minutes after infection. This inhibition was abolished when
euparin was added beyond that time. These results suggest
that the likely euparin mechanism of action would be the
interference with one of the first events of poliovirus repli-
cation cycle probably on the penetration and/or uncoating
process and not the viral RNA replication step. We could
speculate that euparin exert a similar mechanism of action
as other antiviral compounds called capsid binders as the
WIN compounds [30] . These may interact directly with the
viral capsid stabilizing it or preventing the conformational
changes that are required for the uncoating process and the
release of the viral genome into the cellular cytoplasm and
as a result the viral infectivity [31] . Euparin, as well as
these compounds (i.e., V-073), could bind at the innermost
end of the hydrophobic pocket within VP1 [24], but it does
not prevent attachment of the virus to the host cell, leading
to a more rigid capsid making the virus more resistant to
uncoating, thus preventing the RNA delivery to the cellular
cytoplasm. Further studies are necessary to properly define
the mechanism of action of euparin. 10
In addition, the high selectivity activity against poliovirus
in the submicromolar order, specially PV-1, and the specificity
of euparin among the evaluated viruses make this an inter-
esting compound for the development of new antipoliovirus
drugs since many prototype drugs under clinical trials, as
pleconaryl, are unable to inhibit PV-1 [32]. 11
5. Conclusions
In this study we report the antipoliovirus activity of Eupato-
rium buniifolium and the isolation of euparin, as the active
principle responsible for this activity. The results obtained
contribute to describe a new biological activity in a known
compound and suggest that euparin emerges as a new
selective antipoliovirus drug or as a lead molecule for the
developing ofmore potent derivatives. To our knowledge, this
is the first report describing the presence of euparin in E.
buniifolium and also the first detection of its antiviral activity.
Further studies are being undertaken to define the molecular
target of euparin.
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